Hôpital Paul-Brousse

Running trials

• Not yet recruiting

  A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma

  2025-522563-15-00· Phase 2/3· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Source

• Not yet recruiting

  Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy

  NCT07547033· Source

• Recruiting

  Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

  NCT07439939· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Source

• Recruiting

  Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study

  2024-517766-41-00· Phase 2· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Source

• Recruiting

  Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

  NCT06254248· Phase 2· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· Source

• Recruiting

  Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

  NCT07044453· Phase 2/3· Source

• Not yet recruiting

  Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer

  NCT06999512· Phase 2/3· Source

• Recruiting

  Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma

  2024-516233-12-00· Phase 1· Source

• Not yet recruiting

  PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

  NCT07028424· Phase 2· Source

• Not yet recruiting

  Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial

  NCT06263816· Phase 3· Source

• Not yet recruiting

  SIRT and Peri-immunotherapy : a New Concept

  NCT06971237· Source

• Recruiting

  Safety of HRX215 in Patients After Minor and Major Liver Resection

  NCT06638502· Phase 1/2· Source

• Active, not recruiting

  Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC

  2024-516063-89-00· Phase 3· Source

• Active, not recruiting

  Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT06625320· Phase 3· Source

• Recruiting

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· Phase 3· Source

• Recruiting

  Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

  2024-515362-13-00· Phase 2/3· Source

• Active, not recruiting

  Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and immunotherapy ( Pembrolizumab)

  NCT04262687· Phase 2· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Recruiting

  First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

  NCT06253611· Phase 2· Source

• Active, not recruiting

  BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

  NCT05911633· Source

• Recruiting

  ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

  NCT05787197· Source

• Recruiting

  Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients

  NCT05850130· Source

• Active, not recruiting

  TheraSphere With Durvalumab and Tremelimumab for HCC

  NCT05063565· Phase 2· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Source

• Not yet recruiting

  Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma

  NCT05971628· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Source

• Recruiting

  Hepatic and Systemic Hemodynamic Modeling During Liver Surgery

  NCT05339984· Source

• Recruiting

  Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  NCT05528952· Phase 2· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

  NCT05050136· Phase 2· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

• Recruiting

  Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

  NCT04570943· Phase 2· Source

• Active, not recruiting

  Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma

  NCT04791735· Source

• Active, not recruiting

  A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

  NCT04770896· Phase 3· Source

• Active, not recruiting

  OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

  NCT03806309· Phase 2· Source

• Active, not recruiting

  Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

  NCT04421963· Phase 3· Source

• Recruiting

  National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

  NCT04166266· Source

• Active, not recruiting

  Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

  NCT04070443· Phase 2· Source

• Recruiting

  Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

  NCT02885753· Phase 3· Source

• Recruiting

  Chronic Myeloid Leukemia (CML) Real-Life Database

  NCT05963061· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

  NCT00005584· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer15 recruiting
• Liver and biliary tract cancer10 recruiting
• Colorectal cancer4 recruiting
• High blood pressure3 recruiting
• Gastric and esophageal cancer2 recruiting
• Primary biliary cholangitis2 recruiting
• Childhood cancers1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hepatitis B1 recruiting
• Metastatic breast cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular Carcinoma (Morpheus-Neo HCC)

  2022-502840-11-00· Phase 1/2· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Source

• Completed

  Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

  NCT05525520· Phase 2· Source

• Completed

  A Study of Atezolizumab with Lenvatinib or Sorafenib versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated with Atezolizumab and Bevacizumab

  2023-503229-21-00· Phase 3· Source

• Completed

  Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

  NCT04696055· Phase 2· Source

• Completed

  Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma

  NCT04246177· Phase 3· Source

• Completed

  Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)

  NCT04483726· Source

• Completed

  A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

  NCT04039607· Phase 3· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Source

• Completed

  Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

  NCT03841305· Phase 2· Source

• Completed

  Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)

  NCT04069468· Source

• Completed

  "Early TIPS" Versus Glue Obliteration to Prevent Rebleeding From Gastric Varices

  NCT03705078· Source

• Completed

  A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation

  2023-508726-10-00· Phase 3· Source

• Completed

  Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

  NCT02676349· Phase 2· Source

• Completed

  Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions

  NCT02738125· Source

Trial sites

• Hopital Paul Brousse1 trial
• AP-HP - Hôpital Paul Brousse0 trials
• APHP - Hôpital Paul Brousse1 trial
• AP-HP - Hopital Paul-Brousse /ID# 2536460 trials
• AP-HP, Paul Brousse Hospital1 trial
• Centre hépatobiliaire de transplantation hépatique - Hopital Paul Brousse1 trial
• Centre Hépato-Biliaire - Hôpital Paul Brousse1 trial
• Centre Hépato-Biliaire - Hopital Paul-Brousse /ID# 1511521 trial
• Hôpital Paul-Brousse15 trials
• Hôpital Paul-Brousse - Centre Hepato-Biliaire (CHB)1 trial
• Hôpital Paul Brousse - Radiology Department1 trial
• Hopital Paul Brousse (Site 0447)1 trial
• Hôpital Paul Brousse - Villejuif1 trial
• Paul Brousse Hospital6 trials
• Hopital Paul Brousse31 trials